Sanofi SAN.PA
Composite 49/100; the shares have moved about 24% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 32/100 — a moderate mark against it.
Income ranks 58/100 — a slight point in its favour. Quality ranks 56/100 — a slight point in its favour. Valuation ranks 55/100 — a slight point in its favour.
Growth ranks 32/100 — a moderate mark against it. Momentum ranks 42/100 — a slight mark against it. Balance-sheet strength ranks 50/100 — a slight mark against it.
What the company does Sanofi SA (SAN.PA) researches, develops, manufactures, and markets therapeutic solutions across immunology, rare diseases, neurology, oncology, and vaccines. Its portfolio includes pediatric vaccines (e.g., poliomyelitis, pertussis, Hib), RSV protection, and combination vaccines for hepatitis A, typhoid, yellow fever, and rabies. The company also collaborates on novel small-molecule programs in oncology and immunology with partners like Exscientia, ABL Bio, and Innate Pharma.
Key financials Sanofi’s profitability metrics include ROE 6%, ROA 4%, ROCE 8%, gross margin 72%, operating margin 20%, and net margin 16%. Revenue grew 6% year-over-year, while EPS declined -11%. Debt/Equity is 0.27, net debt/EBITDA 1.13, and interest coverage is 14.86. The company trades at a forward P/E of 8.99, EV/EBITDA of 12.62, and FCF yield of 19%.
Stock health Sanofi’s stock shows mixed momentum: up 5.72% over 3 months, 9.48% over 6 months, and 5.04% over 12 months, but down -7.42% from its 52-week high. The RSI(14) is 65.90, indicating moderate bullish momentum. Sideravia’s overall score is 52.3, with Valuation at 64.7 and Income at 14.1.
Price vs fair value The stock trades at a **discount** of 83.20% to our fair-value estimate of 146.37 and a **discount** of 20.29% to the analyst 12-month target of 96.14. - Q2 2026 earnings beat sales and guidance were highlighted, yet the stock fell on pipeline setbacks (Zacks). - Sanofi’s Q2 2026 earnings call emphasized strong sales growth and upgraded guidance (GuruFocus.com). - Recent news mentions rebuilding trust with Regeneron amid pipeline challenges (BioPharma Dive).
Looking forward Sanofi’s forward P/E of 8.99 and PEG of 0.07 suggest potential undervaluation relative to growth, though EPS growth remains negative at -11%. Pipeline collaborations (e.g., Exscientia, ABL Bio) and vaccine portfolio strength may support long-term value. Analysts (n=23) target a 96.14 price, implying ~20% upside from current levels.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.